Mana Up cofounder Meli James to talk about what makes Hawaii brands successful at Hawaii-Made Conference
Story Highlights Hawaii-Made Conference returns May 20 at Hawaii Convention Center.
Mana Up co-founder Meli James to deliver keynote speech.
Conference features industry discussions, networking.
A conference centered around manufacturing and producing in the Islands is returning for its third annual event on May 20 at the Hawaii Convention Center with a keynote speech by Meli James, co-founder of local product business accelerator Mana Up.
The Hawaii-Made Conference, hosted by the Department of Business, Economic Development and Tourism's Business Development and Support Division, is for local food and beverage manufacturers, supply chain operators, policymakers, importers, wholesalers, retailers and other stakeholders. James will speak in her keynote about what makes Hawaii-made brands successful, consumer trends, and how local companies can scale.
'This conference underscores our commitment to strengthening Hawaii's manufacturing sector and creating an environment where locally made products can succeed here at home as well as in national and international markets,' said Dennis Ling, administrator of DBEDT's Business Development and Support Division, in a statement. 'It's also an opportunity for business owners to connect with experts and each other to find practical solutions and new opportunities for growth.'
DBEDT said that the conference will feature industry leaders discussing 'key issues related to product development, commercialization and market expansion.' Topics covered will include sales strategies at consumer events, marketing to visitor markets, early-stage food product development and more. The event also will include networking opportunities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
EU plan would limit Chinese device makers in Europe
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. European Union member states this week voted to support a plan to adopt measures that would restrict Chinese medical device makers' access to the EU market. The member states took the action, under the EU's International Procurement Instrument, after concluding an investigation in January that looked at China's practices in the public procurement market for medical devices. The investigation found that government practices unfairly encouraged Chinese hospitals to choose domestic manufacturers' products. 'The Commission has identified measures and practices in the Chinese procurement market that lead to discrimination against EU operators and EU-made supplies,' Olof Gill, commission spokesperson, said Thursday in an emailed statement. 'This discrimination also harms both the Chinese healthcare infrastructure, which is deprived of quality equipment, and EU businesses, with a high cost in terms of jobs and economic activity in the EU.' The commission has discussed its concerns with Chinese authorities. However, a satisfactory solution has not been proposed, and the EU had no other option than to tackle the issue through an IPI investigation, Gill wrote. The commission said it could not disclose the content of the draft IPI measure or next steps in the process. Chinese manufacturers would be prohibited from bidding on public procurement contracts worth more than 5 million euros for five years. In addition, no more than 50% of a contract's value may be subcontracted to Chinese entities or include Chinese-origin medical devices, MedTech Europe said in a statement. The trade group said it would provide further updates once the IPI measures are published in the EU's official journal. The EU investigation into China's medical device procurement practices was the first use of the IPI, which was introduced in 2022. Getting fair access to Chinese markets became more challenging for medical device companies after the country launched a program calling for domestically produced medical equipment to achieve 50% market penetration in county-level hospitals by 2020 and 70% by 2025, according to a statement from the European Chamber, which represents European businesses in China. European and Chinese leaders will meet in July at a summit in Beijing. Recommended Reading EU mulls retaliation after showing China's bias against foreign device firms Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
38 minutes ago
- Yahoo
Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada
TORONTO, ON / / June 6, 2025 / Two proudly Canadian pharmaceutical companies announced today a strategic partnership that reinforces their shared commitment to serving Canadian patients. Under the agreement, Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma product portfolio across Canada. This landmark collaboration unites two homegrown Canadian pharmaceutical organizations, both with deep roots in the Canadian healthcare landscape. The partnership exemplifies Canadian innovation and entrepreneurship in action, while strengthening domestic pharmaceutical capabilities and expertise. Built by Canadians for Canadians, both companies have demonstrated their dedication to advancing healthcare solutions that address the unique needs of the Canadian market. This alliance further cements their shared vision of making healthcare more accessible and affordable for patients from coast to coast. "Our partnership with Vimy Pharma marks a big step forward advancing access to critical medicines for Canadians,"said Michael Sine, President of Pharmaris. "This alliance demonstrates our shared commitment to putting Canadian patients first." "We are pleased to partner with Pharmaris in broadening access to essential medicines," stated Farris Smith, President of Vimy Pharma,"as we strive to improve outcomes and make a meaningful difference to patients." ABOUT PHARMARIS CANADA Pharmaris Canada is a pharmaceutical company committed to delivering high-quality healthcare products that support the well-being of Canadians. Pharmaris Canada is part of a large diversified global group based out of Vancouver, B.C started by two pharmacists. The group has business interests spanning pharmaceuticals, residential and commercial real estate, property development, hospitality, mobility solutions, and retail pharmacy operations. Pharmaris Canada offers a distinctive portfolio of over-the-counter (OTC) and generic pharmaceutical products. Our OTC range includes a Canadian-made line of iron supplements and a broad selection of German-manufactured effervescent vitamin tablets. As one of the few companies to successfully integrate branded OTC and generic medicines, Pharmaris has developed strong capabilities in brand management, prescription navigation, and market expansion. With a presence in 16 countries and a team of 585 employees, most of whom have been with the organization for over five years, Pharmaris continues to grow its global footprint through innovation and operational excellence. ABOUT VIMY PHARMA Vimy Pharma is a Canadian pharmaceutical company committed to ensuring a stable, reliable supply of essential medicines, reducing dependence on foreign sources, and supporting good-paying jobs for Canadians in life sciences and advanced manufacturing. Our products are made to the highest standards of quality and safety, meeting rigorous Health Canada guidelines. At Vimy Pharma, our team is inspired by the groundbreaking achievements of Drs. Frederick Banting and Charles Best, and James B. Collip whose discovery in Canada of insulin revolutionized treatments and changed millions of lives worldwide. Their spirit of ingenuity, collaboration, and commitment to public health continues to guide our approach as we develop and manufacture high-quality, affordable, essential medicines for Canadian health challenges. MEDIA CONTACTMichael SinePresident, Pharmaris Canadamichael@ Farris SmithFounder & President, Vimy Pharmaceuticals - 30 - SOURCE: Pharmaris View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
an hour ago
- Epoch Times
Senators Demand Investigation Into Possible Chinese ‘Kill Switches' in US Power Grid
Two Republican senators are urging the Commerce Department to launch an immediate investigation into Chinese-made solar products, given the possibility that the Chinese regime could weaponize them to undermine U.S national security. Sens. Rick Scott (R-Fla.) and Marsha Blackburn (R-Tenn.) sent
